Current Allergy and Asthma Reports

, Volume 7, Issue 3, pp 209–215

The role of antileukotriene drugs in management of rhinitis and rhinosinusitis



Antileukotriene drugs have been studied for more than 15 years. In his review we examine the role of leukotrienes in rhinitis and rhinosinusitis, and explore the clinical literature supporting the use of antileukotriene agents in these diseases. Although these medications clearly are efficacious in rhinitis, it is unclear where in the armamentarium they should be used. The evidence for use in sinusitis has not been well studied except in sinusitis-associated aspirin-exacerbated respiratory disease. In this circumstance there is information that allows use of antileukotriene agents to be considered effi cacious. We provide our rationale for use and await future clinical studies to answer this important question.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Drazen JM, Israel E, O’Byrne PM: Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999, 340:197–206.PubMedCrossRefGoogle Scholar
  2. 2.
    Crofford LJ: COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl 1997, 49:15–19.PubMedGoogle Scholar
  3. 3.
    Levy BD: Lipoxins and lipoxin analogs in asthma. Prostaglandins Leukot Essent Fatty Acids 2005, 73:231.PubMedCrossRefGoogle Scholar
  4. 4.
    Yokomizo T, Kato K, Terawaki K, et al.: A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J Exp Med 2000, 192:421–432.PubMedCrossRefGoogle Scholar
  5. 5.
    Yokomizo T, Izumi T, Chang K, et al.: A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature 1997, 387:620–624.PubMedCrossRefGoogle Scholar
  6. 6.
    Islam SA, Thomas SY, Hess C, et al.: The leukotriene B4 lipid chemoattractant receptor BLT1 defi nes antigen-primed T cells in humans. Blood 2006, 107:444–453.PubMedCrossRefGoogle Scholar
  7. 7.
    Sampson AP, Castling DP, Green CP, Price JF: Persistent increase in plasma and urinary leukotrienes after acute asthma. Arch Dis Child 1995, 73:221–225.PubMedCrossRefGoogle Scholar
  8. 8.
    Wenzel SE, Szefler SJ, Leung DY, et al.: Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high-dose glucocorticoids. Am J Respir Crit Care Med 1997, 156:737–743.PubMedGoogle Scholar
  9. 9.
    Zaitsu M, Hamasaki Y, Ishii K, et al.: Direct evidence that LTC4 and LTB4 but not TXA2 are involved in asthma attacks in children. J Asthma 1998, 35:445–448.PubMedCrossRefGoogle Scholar
  10. 10.
    Sjostrom M, Jakobsson PJ, Heimburger M, et al.: Human umbilical vein endothelial cells generate leukotriene C4 via microsomal glutathione S-transferase type 2 and express the CysLT(1) receptor. Eur J Biochem 2001, 268:2578–2586.PubMedCrossRefGoogle Scholar
  11. 11.
    Bartosz G, Konig J, Keppler D, Hagmann W: Human mast cells secreting leukotriene C4 express the MRP1 gene-encoded conjugate export pump. Biol Chem 1998, 379:1121–1126.PubMedCrossRefGoogle Scholar
  12. 12.
    Austen KF: The role of arachidonic acid metabolites in local and systemic inflammatory processes. Drugs 1987, 33:10–17.PubMedCrossRefGoogle Scholar
  13. 13.
    Feinmark SJ, Cannon PJ: Endothelial cell leukotriene C4 synthesis results from intercellular transfer of leukotriene A4 synthesized by polymorphonuclear leukocytes. J Biol Chem 1986, 261:16466–16472.PubMedGoogle Scholar
  14. 14.
    Maclouf JA, Murphy RC: Transcellular metabolism of neutrophil-derived leukotriene A4 by human platelets. A potential cellular source of leukotriene C4. J Biol Chem 1988, 263:174–181.PubMedGoogle Scholar
  15. 15.
    Frolich JC, Fauler J, Tsikas D: Assessment of cysteinyl leukotriene synthesis in man. J Lipid Mediat Cell Signal 1994, 9:75–78.PubMedGoogle Scholar
  16. 16.
    Lynch KR, O’Neill GP, Liu Q, et al.: Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999, 399:789–793.PubMedCrossRefGoogle Scholar
  17. 17.
    Sarau HM, Ames RS, Chambers J, et al.: Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 1999, 56:657–663.PubMedGoogle Scholar
  18. 18.
    Zhu J, Qiu YS, Figueroa DJ, et al.: Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 2005, 33:531–540.PubMedCrossRefGoogle Scholar
  19. 19.
    Heise CE, O’Dowd BF, Figueroa DJ, et al.: Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 2000, 275:30531–30536.PubMedCrossRefGoogle Scholar
  20. 20.
    Corrigan C, Mallett K, Ying S, et al.: Expression of the cysteinyl leukotriene receptors cysLT1 and cysLT2 in aspirin-sensitive and aspirin-tolerant chronic rhinosinusitis. J Allergy Clin Immunol 2005, 115:316.PubMedCrossRefGoogle Scholar
  21. 21.
    Peters-Golden M, Gleason MM, Togias A: Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis. Clin Exp Allergy 2006, 36:689–703.PubMedCrossRefGoogle Scholar
  22. 22.
    Philip G, Malmstrom K, Hampel FC, et al.: Montelukast for treating seasonal allergic rhinitis: a randomized, doubleblind, placebo-controlled trial performed in the spring. Clin Exp Allergy 2002, 32:1020–1028.PubMedCrossRefGoogle Scholar
  23. 23.
    van Adelsberg J, Philip G, LaForce CF, et al.: Randomized controlled trial evaluating the clinical benefi t of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003, 90:214–222.PubMedGoogle Scholar
  24. 24.
    Grayson M, Korenblat P: The emerging role of leukotriene modifiers in allergic rhinitis. Am J Respir Med 2003, 2:441–450.PubMedGoogle Scholar
  25. 25.
    Knapp HR: Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990, 323:1745–1748.PubMedGoogle Scholar
  26. 26.
    Flowers BK, Proud D, Kagey-Sobotka A, et al.: The effect of a leukotriene antagonist on the early response to antigen. Otolaryngol Head Neck Surg 1990, 102:219–224.PubMedGoogle Scholar
  27. 27.
    Israel E, Fischer AR, Rosenberg MA, et al.: The pivotal role of 5-lipoxygenase products in the reaction of aspirinsensitive asthmatics to aspirin. Am Rev Respir Dis 1993, 148:1447–1451.PubMedGoogle Scholar
  28. 28.
    Fischer AR, Rosenberg MA, Lilly CM, et al.: Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994, 94:1046–1056.PubMedCrossRefGoogle Scholar
  29. 29.
    Donnelly AL, Glass M, Minkwitz MC, Casale TB: The leukotriene D4-receptor antagonist, ICI 204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 1995, 151:1734–1739.PubMedGoogle Scholar
  30. 30.
    Dahlen B, Nizankowska E, Szczeklik A, et al.: Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998, 157:1187–1194.PubMedGoogle Scholar
  31. 31.
    Numata T, Konno A, Yamakoshi T, et al.: Comparative role of peptide leukotrienes and histamine in the development of nasal mucosal swelling in nasal allergy. Ann Otol Rhinol Laryngol 1999, 108:467–473.PubMedGoogle Scholar
  32. 32.
    Pullerits T, Praks L, Skoogh BE, et al.: Randomized placebo-controlled study comparing a leukotriene receptor antagonist and a nasal glucocorticoid in seasonal allergic rhinitis. Am J Respir Crit Care Med 1999, 159:1814–1818.PubMedGoogle Scholar
  33. 33.
    Parnes SM, Chuma AV: Acute effects of antileukotrienes on sinonasal polyposis and sinusitis. Ear Nose Throat J 2000, 79:18-20, 24–15.Google Scholar
  34. 34.
    Kütting B, Nieschalk M, Brehler R: A new concept for treatment of sinonasal polyposis. Allergy 2000, 55:1091–1092.PubMedCrossRefGoogle Scholar
  35. 35.
    Meltzer EO, Malmstrom K, Lu S, et al.: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlled clinical trial. J Allergy Clin Immunol 2000, 105:917–922.PubMedCrossRefGoogle Scholar
  36. 36.
    Wilson A, Dempsey OJ, Sims EJ, et al.: Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy 2000, 30:833–838.PubMedCrossRefGoogle Scholar
  37. 37.
    Wilson AM, Orr LC, Sims EJ, Lipworth BJ: Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin Exp Allergy 2001, 31:61–68.PubMedCrossRefGoogle Scholar
  38. 38.
    Corren J, Spector S, Fuller L, et al.: Effects of zafi rlukast upon clinical, physiologic, and inflammatory responses to natural cat allergen exposure. Ann Allergy Asthma Immunol 2001, 87:211–217.PubMedCrossRefGoogle Scholar
  39. 39.
    Wilson AM, Dempsey OJ, Sims EJ, Lipworth BJ: A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001, 31:616–624.PubMedCrossRefGoogle Scholar
  40. 40.
    Nayak AS, Philip G, Lu S, et al.: Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002, 88:592–600.PubMedGoogle Scholar
  41. 41.
    Wilson AM, Orr LC, Coutie WJ, et al.: A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin Exp Allergy 2002, 32:126–132.PubMedCrossRefGoogle Scholar
  42. 42.
    Chen ST, Lu KH, Sun HL, et al.: Randomized placebo-controlled trial comparing montelukast and cetirizine for treating perennial allergic rhinitis in children aged 2–6 yr. Pediatr Allergy Immunol 2006, 17:49–54.PubMedCrossRefGoogle Scholar
  43. 43.
    Lee DK, Jackson CM, Soutar PC, et al.: Effects of single or combined histamine H1-receptor and leukotriene CysLT1-receptor antagonism on nasal adenosine monophosphate challenge in persistent allergic rhinitis. Br J Clin Pharmacol 2004, 57:714–719.PubMedCrossRefGoogle Scholar
  44. 44.
    Kurowski M, Kuna P, Gorski P: Montelukast plus cetirizine in the prophylactic treatment of seasonal allergic rhinitis: influence on clinical symptoms and nasal allergic inflammation. Allergy 2004, 59:280–288.PubMedCrossRefGoogle Scholar
  45. 45.
    Ciprandi G, Tosca MA, Milanese M, et al.: Antihistamines added to an antileukotriene in treating seasonal allergic rhinitis:histamine and leukotriene antagonism. Allerg Immunol (Paris) 2004, 36:67–70, 72.Google Scholar
  46. 46.
    Moinuddin R, de Tineo M, Maleckar B, et al.: Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004, 92:73–79.PubMedCrossRefGoogle Scholar
  47. 47.
    Mucha SM, de Tineo M, Naclerio RM, Baroody FM: Comparison of montelukast and pseudoephedrine in the treatment of allergic rhinitis. Arch Otolaryngol Head Neck Surg 2006, 132:164–172.PubMedCrossRefGoogle Scholar
  48. 48.
    Ratner PH, Howland WC, Arastu R, et al.: Fluticasone propionate aqueous nasal spray provided signifi cantly greater improvement in daytime and nighttime nasal symptoms of seasonal allergic rhinitis compared with montelukast. Ann Allergy Asthma Immunol 2003, 90:536–542.PubMedGoogle Scholar
  49. 49.
    Martin BG, Andrews CP, van Bavel JH, et al.: Comparison of fluticasone propionate aqueous nasal spray and oral montelukast for the treatment of seasonal allergic rhinitis symptoms. Ann Allergy Asthma Immunol 2006, 96:851–857.PubMedCrossRefGoogle Scholar
  50. 50.
    Saengpanich S, de Tineo M, Naclerio RM, Baroody FM: Fluticasone nasal spray and the combination of loratadine and montelukast in seasonal allergic rhinitis. Arch Otolaryngol Head Neck Surg 2003, 129:557–562.PubMedCrossRefGoogle Scholar
  51. 51.
    Pullerits T, Praks L, Ristioja V, Lotvall J: Comparison of a nasal glucocorticoid, antileukotriene, and a combination of antileukotriene and antihistamine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 2002, 109:949–955.PubMedCrossRefGoogle Scholar
  52. 52.
    Di Lorenzo G, Pacor ML, Pellitteri ME, et al.: Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004, 34:259–267.PubMedCrossRefGoogle Scholar
  53. 53.
    Kieff DA, Busaba NY: Effi cacy of montelukast in the treatment of nasal polyposis. Ann Otol Rhinol Laryngol 2005, 114:941–945.PubMedGoogle Scholar
  54. 54.
    Mostafa BE, Abdel Hay H, Mohammed HE, Yamani M: Role of leukotriene inhibitors in the postoperative management of nasal polyps. ORL J Otorhinolaryngol Relat Spec 2005, 67:148–153.PubMedGoogle Scholar
  55. 55.
    Meltzer EO, Hamilos DL, Hadley JA, et al.: Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol 2006, 118:S17–61.PubMedCrossRefGoogle Scholar
  56. 56.
    Daffern PJ, Muilenburg D, Hugli TE, Stevenson DD: Association of urinary leukotriene E4 excretion during aspirin challenges with severity of respiratory responses. J Allergy Clin Immunol 1999, 104:559–564.PubMedCrossRefGoogle Scholar
  57. 57.
    Sousa AR, Parikh A, Scadding G, et al.: Leukotrienereceptor expression on nasal mucosal inflammatory cells in aspirin-sensitive rhinosinusitis. N Engl J Med 2002, 347:1493–1499.PubMedCrossRefGoogle Scholar
  58. 58.
    Stevenson DD, Szczeklik A: Clinical and pathologic perspectives on aspirin sensitivity and asthma. J Allergy Clin Immunol 2006, 118:773–786.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2007

Authors and Affiliations

  1. 1.Division of Allergy and Immunology, Department of Internal MedicineWashington University School of MedicineSt. LouisUSA

Personalised recommendations